CHICAGO – With the failure of Avastin to improve overall survival in a pair of studies in first-line glioblastoma, Roche/Genentech Inc. is again in the position of taking discordant confirmatory data to FDA in support of an accelerated approval, only this time they may have support from quality-of-life data.
Two separate studies looking at Avastin (bevacizumab) in first-line glioblastoma multiforme were presented at the American Society of Clinical Oncology...